Brain-computer interface
Live · Updated 2026

Brain-Computer Interfaces

Neuralink, neurochips, AI neural decoding & the neurotechnological era

From Neuralink human trials and AI-powered speech decoding to non-invasive EEG headsets and bidirectional closed-loop systems — explore the technology connecting brains to machines.

Explore Topics → Read FAQ
$3.2B BCI market 2026
21 Neuralink implants across 4 nations
$1.6B VC funding raised 2025–2026
62 WPM Speech decoding record
Neural implant surgery
$3.2B Market • 21 Neuralink Implants • 62 WPM Speech Neuralink Blindsight • Synchron Stentrode • Non-Invasive EEG AI + BCI • Speech Decoding • Neural Rights China NEO Approval • Clinical Trials • Consumer Neurotech $3.2B Market • 21 Neuralink Implants • 62 WPM Speech Neuralink Blindsight • Synchron Stentrode • Non-Invasive EEG AI + BCI • Speech Decoding • Neural Rights China NEO Approval • Clinical Trials • Consumer Neurotech $3.2B Market • 21 Neuralink Implants • 62 WPM Speech Neuralink Blindsight • Synchron Stentrode • Non-Invasive EEG AI + BCI • Speech Decoding • Neural Rights China NEO Approval • Clinical Trials • Consumer Neurotech
Market Overview

The $3.2 Billion BCI Market

Clinical invasive BCIs and consumer non-invasive neurotechnology — the two paths of brain-computer interfaces.

Brain-Computer Interface Market Overview & Growth Forecast
Market Overview

Brain-Computer Interface Market Overview & Growth Forecast

A $3.2 billion market in 2026, projected to reach $6–12 billion by 2030 at 15–18% CAGR — bifurcating into clinical invasive BCIs and consumer non-invasive neurotechnology.

Clinical Trial Momentum: Multiple companies simultaneously enrolling patients across 4+ countries. Synchron preparing pivotal study for FDA PMA by 2028.
AI + BCI Convergence: LLM integration enabling fluent natural language from sparse neural signals. Transformer-based decoders achieving 62 WPM speech restoration.
Record VC Investment: $1.6B+ raised in 2025–2026 YTD. Neuralink $650M, Synchron $200M, Merge Labs $252M, Science Corp $230M.
Consumer Neurotech Maturation: EMOTIV, Neurable expanding market for productivity, gaming, and accessibility. EEG headsets achieving clinically meaningful signal resolution.
BCI Key Players & Devices: 2026 Landscape
Key Players

BCI Key Players & Devices: 2026 Landscape

Six companies in human trials. China approved the world's first commercial invasive BCI. The race between invasive precision and non-invasive accessibility is on.

Neuralink N1 Implant (Telepathy): IDE
Neuralink Blindsight: Breakthrough
Stentrode: Breakthrough
Connexus Direct Data Interface: IDE
Technology Comparison

Invasive vs Non-Invasive

The trade-offs between surgical precision and accessibility in brain-computer interfaces.

Invasive BCI

Invasive BCI

Signal Quality High (direct neural recording)
Spatial Resolution Single neuron level
Surgical Risk Yes — craniotomy or endovascular
Regulatory Path FDA IDE / PMA (years)
Non-Invasive BCI

Non-Invasive BCI

Signal Quality Moderate (attenuated by skull)
Spatial Resolution Centimeter scale
Surgical Risk None
Regulatory Path Consumer product (months)
AI Convergence

AI + BCI Revolution

Transformer-based neural decoders and LLM integration transforming brain signals into fluent speech.

Speech Decoding at 62 WPM
Breakthrough

Speech Decoding at 62 WPM

Stanford/BrainGate achieved 62 words per minute — approaching natural speech rate of ~150 WPM. UCSF team decoded full sentences from a paralyzed ALS patient.

LLM Integration for Fluent Language
Breakthrough

LLM Integration for Fluent Language

Large language models retrained on neural signal corpora enable BCI systems to decode intended speech with accuracy levels making real-world deployment practical.

Deep Learning Neural Decoders
Breakthrough

Deep Learning Neural Decoders

Deep neural networks dramatically improved signal processing. Reduced calibration burden on end users. Real-time neural signal interpretation at low power via edge AI processors.

Handwriting Decoding
Breakthrough

Handwriting Decoding

BrainGate decoded imagined handwriting at 90 characters per minute with 94% accuracy. Transformer models translating neural pen trajectories to text.

Key Devices

Leading BCI Devices

The devices shaping the future of brain-computer interfaces.

Neuralink N1 Implant (Telepathy)

Neuralink N1 Implant (Telepathy)

Neuralink

1,024 electrode threads thinner than human hair. 21 patients implanted across 4 nations. Cursor control, working toward speech decoding.

1,024 electrodes
Neuralink Blindsight

Neuralink Blindsight

Neuralink

Cortical visual prosthesis. First-in-human implant in 2026. Aims to restore vision to blind patients.

1,024 electrodes
Stentrode

Stentrode

Synchron

Inserted via blood vessels — no open brain surgery. Completed US feasibility trial, preparing pivotal study for FDA PMA by 2028.

16 electrodes
Connexus Direct Data Interface

Connexus Direct Data Interface

Paradromics

High-bandwidth speech restoration BCI. Connect-One first chronic implant opened at University of Michigan, February 2026.

1,684 electrodes
Layer 7 Cortical Interface

Layer 7 Cortical Interface

Precision Neuroscience

Sits on top of brain without penetrating tissue. FDA 510(k) clearance granted. Moving toward chronic wireless implant study.

1,024 electrodes
NEO BCI

NEO BCI

Neuracle (China)

World's first approved invasive BCI product beyond clinical trials. Approved in China for spinal cord injury paralysis. Incorporated into health insurance.

8 electrodes
2026 → 2030

The Neural Path Ahead

Five predictions for the future of brain-computer interfaces.

2026
2026
Neuralink Blindsight first-in-human
Paradromics Connect-One chronic implant. BCI market crosses $3.5B. Non-invasive consumer EEG OEM partnerships expand.
2027
2027
FDA guidance on adaptive neurostimulation finalized
Closed-loop BCIs for depression enter pivotal trials. First bidirectional BCI with sensory feedback in humans.
2028
2028
Synchron FDA PMA approval — first commercial endovascular BCI in US
Speech BCIs achieving natural-speed communication (100+ WPM). Potential BCI IPO activity.
2029
2029
10,000-electrode BCIs entering clinical trials
Neural rights legislation passed in multiple jurisdictions. Consumer EEG achieving real-time silent speech interfaces.
2030
2030
BCI market reaches $6–12B
FDA-approved thought-based communication for ALS. First cognitive enhancement applications begin clinical testing. Consumer-grade BCI devices mainstream.
FAQ

Frequently Asked Questions

Structured answers to the most common BCI questions — optimized for AI search citation.

What is a brain-computer interface?
A brain-computer interface (BCI) is a system that records electrical, chemical, or optical signals from neural tissue and translates them into digital commands, while optionally delivering stimulation back to the brain. Modern BCI systems integrate AI-based signal decoders, wireless transmission, and edge computing for real-time human-machine interaction. BCIs can be invasive (requiring surgery) or non-invasive (using scalp electrodes).
How does Neuralink work?
Neuralink's N1 Implant uses 1,024 ultra-thin electrode threads — each thinner than a human hair — implanted directly into the motor cortex to record neural signals. A surgical robot inserts the threads with micron precision. The signals are wirelessly transmitted to an external device where AI algorithms decode the user's intentions into digital actions like cursor control. As of 2026, 21 patients have been implanted across 4 nations. Neuralink is also developing Blindsight, a cortical visual prosthesis to restore vision.
What is the difference between invasive and non-invasive BCI?
Invasive BCIs require surgery to implant electrodes directly on or in the brain, offering high signal fidelity and single-neuron resolution but carrying surgical risks. Non-invasive BCIs use scalp-mounted EEG electrodes, requiring no surgery but providing lower signal quality attenuated by the skull. Invasive BCIs are used for clinical applications like paralysis and ALS, while non-invasive BCIs serve consumer markets like gaming, focus monitoring, and meditation. AI-based spatial filtering is helping close the quality gap for non-invasive systems.
How fast can BCI speech decoding work?
The current record for BCI speech decoding is 62 words per minute, achieved by Stanford/BrainGate using intracortical electrodes and transformer-based AI decoders. This approaches the natural speech rate of ~150 WPM. UCSF researchers have decoded full sentences from a paralyzed ALS patient. BrainGate also decoded imagined handwriting at 90 characters per minute with 94% accuracy. By 2028, speech BCIs are expected to achieve natural-speed communication.
How big is the BCI market?
The global brain-computer interface market was valued at approximately $2.8 billion in 2025 and is estimated at $3.2 billion in 2026. Projections from Grand View Research, MarketsandMarkets, and Global Market Insights put the market at $6–12 billion by 2030, representing a 15–18% CAGR. The fastest-growing segments are clinical-stage implantable communication BCIs and non-invasive consumer EEG devices. Deep brain stimulation currently constitutes the largest segment by revenue.
Are brain-computer interfaces safe?
Invasive BCIs carry surgical risks including hemorrhage, infection, and glial scarring that can degrade signals over time. However, newer approaches like Synchron's endovascular Stentrode avoid open brain surgery by inserting devices through blood vessels. China's NEO device was approved partly because its epi-cortical design presents lower risk than penetrating implants. Non-invasive BCIs have no surgical risk. The FDA has granted breakthrough device designations to several BCI systems, and over 4,000 patients have been safely implanted with NeuroPace RNS for epilepsy.
What is Synchron's Stentrode and how is it different from Neuralink?
Synchron's Stentrode is an endovascular BCI implanted through the blood vessels — no open brain surgery required. A catheter inserts the device into a blood vessel on the surface of the motor cortex. This approach dramatically reduces surgical risk compared to Neuralink's craniotomy-based implant. Synchron has FDA breakthrough device designation and has implanted patients in the US and Australia. The trade-off is lower electrode count (16 contacts vs Neuralink's 1,024), but the safety profile makes it the leading candidate for first commercial BCI approval in the US.
What are neural rights?
Neural rights are legal protections for cognitive liberty, mental privacy, and mental integrity in the era of neurotechnology. Chile became the first country to amend its constitution to include neural rights in 2021. The US states of Colorado and Minnesota have passed neural privacy legislation. The concern is that BCIs could eventually allow third parties to access or manipulate neural data. The NeuroRights Foundation advocates for five fundamental neural rights: cognitive liberty, mental privacy, mental integrity, psychological continuity, and fair access.
BCI character

Connect Your Mind

Get the latest BCI breakthroughs, Neuralink updates, and neurotechnology insights delivered weekly.

Explore BCI Articles →
🧠 Neuralink updates 🗣️ Speech decoding ⚡ Neural rights